Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T14:15:41.504Z.
Calculation as of: 2026-10-06T14:15:41.504Z.
Quote observation: 2026-10-06T14:15:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 66e3eaee1cdd755dffe0dd2f4d89b3fc137545160e5faabf240127d9674bae42
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$178.23M
PS Ratio
119.15
TTM Avg
325.04
3Y Avg
325.04
5Y Avg
325.04
Market Cap
$173.51M
PS Ratio
N/A
TTM Avg
344.10
3Y Avg
344.10
5Y Avg
344.10
Market Cap
$170.58M
PS Ratio
3.79
TTM Avg
34.48
3Y Avg
14.27
5Y Avg
9.83
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | $191.07M | N/A | N/A | N/A | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $191.04M | N/A | N/A | N/A | N/A |
| Journey Medical Corporation (DERM)vs › | $181.64M | 2.66 | 2.93 | 2.14 | 1.57 |
| Electra Therapeutics Inc. (ETRA)vs › | $200.03M | N/A | N/A | N/A | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $178.23M | 119.15 | 325.04 | 325.04 | 325.04 |
| Compass Therapeutics, Inc. (CMPX)vs › | $173.51M | N/A | 344.10 | 344.10 | 344.10 |
| Cue Biopharma, Inc. (CUE)vs › | $175.98M | 4.67 | 4.86 | 10.20 | 38.22 |
| Alector, Inc. (ALEC)vs › | $208.17M | 15.02 | 8.68 | 5.87 | 7.02 |
| Precision BioSciences, Inc. (DTIL)vs › | $170.58M | 3.79 | 34.48 | 14.27 | 9.83 |
| MediWound Ltd. (MDWD)vs › | $173.67M | 14.64 | 12.04 | 9.32 | 6.72 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-12 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-17 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-11 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-11 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
